Q4 2021 Results slide image

Q4 2021 Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix Harry Kirsch Chief Financial Officer Financial review and 2022 guidance 39 Investor Relations | Q4 2021 Results U NOVARTIS | Reimagining Medicine
View entire presentation